Equities research analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to post sales of $441.37 million for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Jazz Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $428.99 million and the highest estimate coming in at $449.74 million. Jazz Pharmaceuticals reported sales of $396.62 million in the same quarter last year, which indicates a positive year over year growth rate of 11.3%. The business is scheduled to report its next earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full-year sales of $441.37 million for the current financial year, with estimates ranging from $1.61 billion to $1.63 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $1.85 billion per share, with estimates ranging from $1.79 billion to $1.96 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Jazz Pharmaceuticals.

Several brokerages have recently commented on JAZZ. J P Morgan Chase & Co reiterated a “buy” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 18th. Royal Bank of Canada reiterated a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, September 15th. BMO Capital Markets reiterated a “buy” rating and issued a $196.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, September 20th. Morgan Stanley began coverage on shares of Jazz Pharmaceuticals in a report on Thursday, October 5th. They issued an “equal weight” rating and a $155.00 target price for the company. Finally, Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a report on Thursday, September 28th. They issued a “neutral” rating and a $165.00 target price for the company. Two research analysts have rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $181.28.

In other Jazz Pharmaceuticals news, Director Patrick G. Enright sold 352 shares of the stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $133.19, for a total transaction of $46,882.88. Following the completion of the transaction, the director now owns 1,365 shares in the company, valued at $181,804.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Iain Mcgill sold 8,000 shares of the stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the transaction, the senior vice president now owns 28,383 shares of the company’s stock, valued at approximately $3,786,859.86. The disclosure for this sale can be found here. Insiders have sold 9,352 shares of company stock valued at $1,264,243 in the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of the business. AXA boosted its position in Jazz Pharmaceuticals by 23.2% during the third quarter. AXA now owns 116,862 shares of the specialty pharmaceutical company’s stock worth $17,091,000 after purchasing an additional 22,007 shares during the period. Neuberger Berman Group LLC boosted its position in Jazz Pharmaceuticals by 26.6% during the third quarter. Neuberger Berman Group LLC now owns 117,345 shares of the specialty pharmaceutical company’s stock worth $17,162,000 after purchasing an additional 24,626 shares during the period. California Public Employees Retirement System boosted its position in Jazz Pharmaceuticals by 4.8% during the third quarter. California Public Employees Retirement System now owns 122,201 shares of the specialty pharmaceutical company’s stock worth $17,872,000 after purchasing an additional 5,601 shares during the period. Virtu Financial LLC bought a new position in Jazz Pharmaceuticals during the third quarter worth about $291,000. Finally, Janney Montgomery Scott LLC boosted its position in shares of Jazz Pharmaceuticals by 29.4% in the third quarter. Janney Montgomery Scott LLC now owns 1,760 shares of the specialty pharmaceutical company’s stock valued at $257,000 after acquiring an additional 400 shares during the period. Hedge funds and other institutional investors own 91.30% of the company’s stock.

Shares of Jazz Pharmaceuticals (JAZZ) opened at $140.00 on Tuesday. The company has a market cap of $8,331.32, a PE ratio of 17.44, a PEG ratio of 0.90 and a beta of 0.98. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63. Jazz Pharmaceuticals has a 1-year low of $101.44 and a 1-year high of $163.75.

WARNING: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/12/brokerages-anticipate-jazz-pharmaceuticals-plc-jazz-will-post-quarterly-sales-of-441-37-million.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.